Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer
Journal
Future Oncology
Journal Volume
15
Journal Issue
20
Pages
2371-2383
Date Issued
2019
Author(s)
Woodford R
Loh Y
Lee J
Cooper W
Marschner I
Lewis C.R
Millward M
Lord S
Gralla R.J
Mok T
Lee C.K.
Abstract
We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials. ? 2019 Future Medicine Ltd.
Subjects
chemoimmunotherapy; meta-analysis; non-small-cell lung cancer; PD-L1 expression; progression-free survival
SDGs
Other Subjects
anaplastic lymphoma kinase; atezolizumab; bevacizumab; carboplatin; cisplatin; durvalumab; epidermal growth factor receptor; gemcitabine; nivolumab; paclitaxel; pembrolizumab; pemetrexed; programmed death 1 ligand 1; antineoplastic agent; CD274 protein, human; immunological antineoplastic agent; programmed death 1 ligand 1; cancer immunotherapy; clinical feature; gender; hazard ratio; histopathology; human; meta analysis; non small cell lung cancer; overall survival; patient selection; phase 3 clinical trial (topic); predictive value; priority journal; progression free survival; protein expression; randomized controlled trial (topic); Review; systematic review; treatment outcome; cancer staging; lung tumor; metabolism; mortality; non small cell lung cancer; pathology; sex factor; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Staging; Patient Selection; Progression-Free Survival; Randomized Controlled Trials as Topic; Sex Factors
Publisher
Future Medicine Ltd.
Type
review